TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03273413
Drug: Pravastatin
Normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anti-inflammatory, anti-oxidative stress, and anti-proliferative therapy
Study: NCT03273413
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive tablet
Study: NCT01270984
Drug: Luckyvec 400mg film coated tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: •400mg/tablet, PO, 1 tablet once daily for Period I \& II D1(crossover)
Study: NCT01270984
Drug: Glivec 100mg film coated tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: •100mg/tablet, PO, 4 tablets once daily for Period I \& II D1(crossover)
Study: NCT00488644
Drug: Levothyroxine
Normalized name: Levothyroxine
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 75 mcg by mouth (PO) Daily for 8 Weeks
Study: NCT00488644
Drug: Liothyronine
Normalized name: Liothyronine
DrugBank: Liothyronine (DB00279)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 15 mcg PO Daily for 8 Weeks
Study: NCT03279757
Drug: AHES 5 minutes
Normalized name: phenylephrine hydrochloride Chewable Tablet [Ah-Chew D]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of AHES with 5 minutes application time After 5 minutes: pain stimulus with the fractional CO2 laser, 50 mJ, 5% density
Study: NCT03279757
Drug: AHES 15 minutes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of AHES with 15 minutes application time After 15 minutes: pain stimulus with the fractional CO2 laser, 50 mJ, 5% density
Study: NCT03279757
Drug: AHES 25 minutes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of AHES with 25 minutes application time After 25 minutes: pain stimulus with the fractional CO2 laser, 50 mJ, 5% density
Study: NCT03279757
Drug: LTC 5 minutes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of LTC with 5 minutes application time After 5 minutes: pain stimulus with the fractional CO2 laser, 50 mJ, 5% density
Study: NCT03279757
Drug: LTC 15 minutes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of LTC with 15 minutes application time After 15 minutes: pain stimulus with the fractional CO2 laser, 50 mJ, 5% density
Study: NCT04002115
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide will be given once a day for 2 days after the transplant infusion.
Study: NCT03546491
Drug: Preventive Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4% Stannous Fluoride
Study: NCT03546491
Drug: Marketed Control
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.243% Sodium Fluoride
Study: NCT04091789
Drug: Pure Femme Tablets
Normalized name: Dream Pure BB
Approvals — FDA: no, EMA: no, PMDA: no
Description: A sublingual tablet containing 30 mg of cannabidiol (CBD), 1 mg tetrahydrocannabinol (THC), 97 mg palmitoylethanolamide (PEA), and a 0.2 mg combination of myrcene, beta-caryophyllene, humulene, linalool, and limonene and peppermint oil.
Study: NCT00994461
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib 100mg tablet twice a day with meal for 2 weeks
Study: NCT00994461
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet three times a day with meal for 2 weeks
Study: NCT02941692
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for Oxytocin
Study: NCT03271281
Drug: One injection of 68Ga-NODAGA-E[c(RGDyK)]2
Approvals — FDA: no, EMA: no, PMDA: no
Description: One injection of 68Ga-NODAGA-E\[c(RGDyK)\]2
Study: NCT04195204
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigators administrated intravenously saline solution as a placebo
Study: NCT03066648
Drug: PDR001
Approvals — FDA: no, EMA: no, PMDA: no
Description: PDR001 is a high-affinity, ligand-blocking, humanized IgG4 monoclonal antibody directed against PD-1 that blocks the binding of PD-L1 and PD-L2.
Study: NCT01710202
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Each subject in this group will receive one 20mg hydrocortisone capsule to be taken by mouth.
Study: NCT00144521
Drug: MRA placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0mg/kg/4week(i.v.) for 24 weeks
Study: NCT00144521
Drug: MTX placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0mg/week(p.o.) for 24 weeks
Study: NCT04443946
Drug: Sufentanil
Normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.01 μ g kg-1 min-1 sufentanil were pumped continuously at maintain phase
Study: NCT01056237
Drug: Multi-target therapy
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tacrolimus (1-3mg/d) and mycophenolate mofetil(0.5-0.75g/d)
Study: NCT01056237
Drug: Azathioprine
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1.0-2.0mg/kg/d
Study: NCT02336568
Drug: PLACEBO
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the first week 24 IU \* 2/day. in the 2nd \& 3rd 40 IU \* 2/day
Study: NCT00097825
Drug: Zoledronic Acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02256124
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02913183
Drug: young Fresh Frozen Plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood plasma from healthy male donors aged 18-30 years old.
Study: NCT02913183
Drug: old Fresh Frozen Plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood plasma from healthy male donors aged 40-55 years old.
Study: NCT01965366
Drug: 0.5 mg DEX
Approvals — FDA: no, EMA: no, PMDA: no
Description: A dose of DEX will be given the night before (approximately 10 hours before) each of 5 to 11 individual virtual reality exposure (VRE) therapy sessions.
Study: NCT00928291
Drug: antibiotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: antibiotic therapy use
Study: NCT02295826
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: participants randomized to ASA therapy will be loaded with 325 mg of ASA, followed by 81 mg/day
Study: NCT01172925
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaler
Study: NCT00022698
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02134015
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo infusion every 3 weeks
Study: NCT03691051
Drug: Pyrotinib plus Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pyrotinib:400mg/d,q.d.,p.o. A course of treatment need 21days. Capecitabine:1000mg/m2,bid,from day1-day14, A course of treatment need 21 days.
Study: NCT03685253
Drug: Niagen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niagen® (3-(Aminocarbonyl)-1-β-D-ribofuranosyl-pyridinium chloride - NR) will be the experimental treatment, at a dose of 1000 mg/day taken as two 250 mg capsules twice daily for 6 months.
Study: NCT03685253
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules matched to the experimental drug and taken orally as 2 capsules twice daily for 6 months.
Study: NCT04143854
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection; normal saline
Study: NCT02705300
Drug: Calcium folinate 200 mg/m2 iv
Approvals — FDA: no, EMA: no, PMDA: no
Description: Max. 6 months
Study: NCT02705300
Drug: 5-fluorouracil 3200 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Max. 6 months
Study: NCT02705300
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Max. 2 years or at the discretion of the investigator
Study: NCT00894439
Drug: BLI-489
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05125796
Drug: Dexketoprofen Trometamol
Normalized name: Dexketoprofen trometamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg intravenous dexketoprofen Trometamol in 100 mL normal saline
Study: NCT05125796
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mL intravenous normal saline infusion+ placebo topical pomade application
Study: NCT03032042
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03032042
Drug: Delayed treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albendazole+Azithromycin
Study: NCT02024607
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02024607
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02024607
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03756623
Drug: Probiotics powder
Normalized name: Nutricia Neocate Syneo Infant Prebiotics + Probiotics Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5g of Probiotics powder administered three times a day orally before meal
Study: NCT00502385
Drug: AZD2171
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00468481
Drug: Drospirenone/Ethinylestradiol/Methyltetrahydrofolate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.020 mg ethinylestradiol with 3.0 mg drospirenone and 0.451 mg L-5-methyltetrahydrofolate (L-5-MTHF)
Study: NCT00468481
Drug: Drospirenone/Ethinylestradiol (Yaz)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.020 mg ethinylestradiol with 3.0 mg drospirenone
Study: NCT00415818
Drug: 1st line Chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02992236
Drug: VAS203
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of NO-Synthase inhibitor VAS203
Study: NCT01234870
Drug: Adenosine
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00044070
Drug: YM872 (zonampanel)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04108468
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate
Study: NCT00734162
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TDF placebo tablet once daily
Study: NCT03298958
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subject will be randomized to one of the 2 arms
Study: NCT03097341
Drug: xisomab 3G3- Dose 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a single intravenous dose of 0.1 mg/kg xisomab 3G3.
Study: NCT03097341
Drug: xisomab 3G3-Dose 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a single intravenous dose of 0.5 mg/kg xisomab 3G3.
Study: NCT03097341
Drug: xisomab 3G3-Dose 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a single intravenous dose of 2.0 mg/kg xisomab 3G3.
Study: NCT03097341
Drug: xisomab 3G3- Dose 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a single intravenous dose of 5.0 mg/kg xisomab 3G3.
Study: NCT01568034
Drug: BIA 9-1067
Normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIA 9-1067 - 25 mg single-dose
Study: NCT01568034
Drug: BIA 9-1067
Normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIA 9-1067 - 50 mg single-dose
Study: NCT01568034
Drug: BIA 9-1067
Normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIA 9-1067 - 100 mg single-dose
Study: NCT01568034
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: single-dose
Study: NCT01568034
Drug: Levodopa/Benzerazide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodopa 100 mg Benzerazide 25 mg
Study: NCT02393950
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral escalating doses of ODM-106 will be administered. Each subject will participate in 4 study periods and will therefore receive 3 single doses of ODM-106 and one single dose of placebo.
Study: NCT01262287
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo capsules in same number as active drug, daily for 8-week treatment period
Study: NCT04527289
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients will be managed with placebo as add on to the standard regimen.
Study: NCT03805568
Drug: remifentanil infusion group
Approvals — FDA: no, EMA: no, PMDA: no
Description: remifentanil as anaesthetic adjuvant
Study: NCT00918411
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT01146093
Drug: Pravastatin Sodium
Normalized name: Pravastatin Sodium
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pravastatin Sodium Tablets 80 mg
Study: NCT02657122
Drug: Placebo for SAD
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAD: Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 5 dose ascending cohorts) to receive either TD-1473 or placebo. The study drug (TD-1473 or placebo) will be administered orally as a single dose.
Study: NCT02657122
Drug: Placebo for MAD
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAD: Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 4 cohorts) to receive either TD-1473 or placebo. The study drug (TD-1473 or placebo) will be administered orally for a total of 14 days of dosing.
Study: NCT04506463
Drug: MM-II dose II
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular injection
Study: NCT04506463
Drug: MM-II dose III
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular injection
Study: NCT04506463
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular injection
Study: NCT01475708
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg PO bid, 14 days
Study: NCT02975388
Drug: RO7079901
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a single dose of 1000 milligrams (mg) RO7079901 as a 30-minute intravenous (IV) infusion.
Study: NCT03205956
Drug: Levodopa
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: At least 1 hour after 200mg carbidopa p.o., each subject will receive an intravenous solution of levodopa in saline at a rate based on age and body mass according to the final dose described in Black et al 2003.The total dose for a 70-year-old, 70kg subject will be approximately 65mg.~Subjects with untreated PD will then take 6 ± 1 weeks of clinically dosed oral carbidopa-levodopa tablets for clinical purposes and then repeat the carbidopa plus intravenous levodopa dose as above.
Study: NCT01232413
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT01232413
Drug: ASP1941
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT03005496
Drug: Zinc
Normalized name: Zinc
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: included in intervention arm
Study: NCT02763137
Drug: Standard LD/CD
Approvals — FDA: no, EMA: no, PMDA: no
Description: LD/CD will be administered at patient's usual dose and frequency during 8 hours interval
Study: NCT02763137
Drug: Semi continuous intra-oral administration of LD/CD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semi continuous intra-oral administration of standard LD/CD at a dose equal to the total dose of standard oral LD/CD that patients would normally consume over 8 hours period.
Study: NCT00324025
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01017770
Drug: Artemether-lumefantrine
Normalized name: artemether-lumefantrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemether-lumefantrine by Novartis was the first fixed-dose ACT that was prequalified by WHO in April 2004. A 3-day, 6-dose regimen of AL is recommended for infants and children weighing 5-35 kg and adults weighing \> 35 kg.
Study: NCT00744965
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham dose adjustments of the placebo will be made.
Study: NCT03128138
Drug: SPH3127
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: SPH3127 Tablet~Drug: Placebo Tablet
Study: NCT02339532
Drug: FEC100
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 cycles of FEC 100 administered IV q3w~* 5-Fluorouracil (5-FU) 500 mg/m²~* Epirubicin 100 mg/m²~* Cyclophosphamide 500 mg/m²
Study: NCT03934736
Drug: HEPLISAV-B®
Approvals — FDA: no, EMA: no, PMDA: no
Description: HEPLISAV-B®, a licensed, commercially-available hepatitis B vaccine for adults 18 years of age and older, consisting of the adjuvant cytidine phosphoguanosine (CpG) 1018 combined with the antigen recombinant hepatitis B surface antigen (rHBsAg).
Study: NCT04173455
Drug: HZ-A-018
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the dose-escalation part, subjects will be assigned to five cohorts with increaing dose level to determine DLT and MTD during the first 28-day cycle.~In the expansion part, subjects will be assigned to two fixed dose corhort.
Study: NCT00026273
Drug: FOLFIRI regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00026273
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00026273
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01998802
Drug: Placebo Comparator
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02737930
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02737930
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02693002
Drug: Estradiol/Norethindrone acetate
Normalized name: Estradiol/Norethindrone Acetate 1 MG-0.5 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estradiol/Norethindrone acetate 1mg/0.5 mg
Study: NCT02693002
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: inactive ingredient
Study: NCT02064816
Drug: Rebif®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rebif® will be administered at a dose of 44 microgram (mcg) subcutaneously three times a week in the morning using RebiSmart® self-injector device for 12 weeks.
Study: NCT02064816
Drug: Rebif®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rebif® will be administered at a dose of 44 mcg subcutaneously three times a week in the evening using RebiSmart® self-injector device for 12 weeks.
Study: NCT01757184
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusions of matched placebo
Study: NCT02260336
Drug: Celecoxib Capsule 400 mg daily
Normalized name: celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00602836
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 600 mg/m\^2 by IV on day 1 of cycles 1-6 (every 21 days)
Study: NCT00865878
Drug: Aminolevulinic Acid
Normalized name: Aminolevulinic Acid
DrugBank: Aminolevulinic acid (DB00855)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20% aminolevulinic acid HCL (ALA) applied topically for 90 +/- 30 minutes prior to treatment with 10 j/cm2 blue light. Up to nine (9) ALA-PDT treatments will be given: The initial four (4) treatments will be given at 4-5 week intervals, with the remaining five (5) treatments given every 6 +/-1 weeks.
Study: NCT02639650
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: methotrexate 100mg/m2, 200mg/m2, ivgtt, tetrahydrofolic acid （FA) 15mg q12h\*4(24h after methotrexate injection),started at the first day of cycle, two weeks a cycle
Study: NCT02639650
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: cyclophosphamide 600mg/m2, started at the 8th day of cycle, two weeks a cycle
Study: NCT01718678
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: it is kind of drug
Study: NCT01718678
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: It is Placebo
Study: NCT01135433
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT00250952
Drug: Botox Cosmetic™
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01377922
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablets administered 3-4 times a day (to the individual patient's tablet count of active at baseline) over 2 weeks.
Study: NCT00586820
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects randomized to the placebo arm will receive a placebo infusion (saline) for 20 minutes prior to PCI.
Study: NCT04153760
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo p.o. daily
Study: NCT01157104
Drug: IDX320
Approvals — FDA: no, EMA: no, PMDA: no
Description: IDX320 400 mg in tablets (8x50 mg) administered orally once daily
Study: NCT01157104
Drug: IDX184
Approvals — FDA: no, EMA: no, PMDA: no
Description: IDX184 100 mg in capsules (2x50 mg) administered orally once daily
Study: NCT01157104
Drug: IDX184 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IDX184 matching placebo in capsules administered orally once daily
Study: NCT01157104
Drug: IDX320 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IDX320 matching placebo in tablets administered orally once daily
Study: NCT03258294
Drug: Melatonin(Circadin®)
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04272944
Drug: 10 mg/kg Q2W
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg MSB2311 every two weeks
Study: NCT04272944
Drug: 20 mg/kg Q3W
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/kg MSB2311 every three weeks.
Study: NCT00602459
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03364400
Drug: VT1021
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peptide
Study: NCT00079001
Drug: zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given IV